Should depot medroxyprogesterone acetate be prescribed to a 40‑year‑old woman with uncontrolled hypertension and multiple cardiovascular risk factors (e.g., smoking, dyslipidemia)?

Should Depot Medroxyprogesterone Acetate Be Prescribed to This Patient?

No, depot medroxyprogesterone acetate (DMPA) should not be prescribed to this 40-year-old woman with uncontrolled hypertension and multiple cardiovascular risk factors. The 2023 AHA/ACC guidelines explicitly state that injectable depot medroxyprogesterone acetate should be avoided among women with chronic coronary disease or previous stroke as both forms of contraceptive therapy increase thrombosis risk 1. While this patient does not have established coronary disease, her uncontrolled hypertension combined with smoking and dyslipidemia places her at substantially elevated cardiovascular risk, making DMPA contraindicated.

Primary Contraindication: Uncontrolled Hypertension

DMPA is absolutely contraindicated when blood pressure exceeds 160/110 mm Hg and should be used with extreme caution when BP ≥140/90 mm Hg 1. The 2025 Circulation guidelines on hypertension in pregnancy and postpartum explicitly classify uncontrolled hypertension as an absolute contraindication to depot medroxyprogesterone injection 1. This patient's uncontrolled hypertension alone disqualifies her from DMPA use.

Multiple Cardiovascular Risk Factors Create Compounding Risk

This patient presents with a cluster of cardiovascular risk factors that synergistically increase her thrombotic and cardiovascular risk:

• Age 40 years: Women over 35 years using DMPA have demonstrated increased cardiovascular risk 1
• Active smoking: Combined with hormonal contraception, smoking substantially increases thromboembolism risk 1
• Dyslipidemia: DMPA itself adversely affects lipid profiles, causing significant increases in LDL cholesterol (120.04 vs 94.27 mg/dL), decreases in HDL cholesterol (39.67 vs 44.13 mg/dL), and increases in triglycerides (126.33 vs 99.03 mg/dL) 2
• Uncontrolled hypertension: The combination of hypertension with other risk factors creates Category 3-4 contraindication status

Evidence of DMPA's Cardiovascular Harm

The cardiovascular risks of DMPA are well-documented through multiple mechanisms:

• Thrombosis risk: The 2023 AHA/ACC guidelines concluded that combined hormonal contraceptives and injectable depot medroxyprogesterone acetate increase thrombosis risk and should be avoided in women with cardiovascular disease or stroke history 1
• Endothelial dysfunction: Research demonstrates that long-term DMPA use significantly impairs endothelium-dependent arterial function (FMD reduced to 1.1% vs 8.0% in controls, p<0.01), likely through hypoestrogenism 3
• Adverse lipid changes: DMPA causes statistically significant worsening of all lipid parameters, with Castelli Index I increasing from 3.02 to 4.61 (p=0.000), indicating substantially elevated cardiovascular disease risk 2
• Glucose metabolism: DMPA significantly increases fasting blood glucose levels (84.6 vs 77.8 mg/dL, p≤0.001), adding metabolic risk 2

FDA Labeling Supports Avoidance

The FDA label for medroxyprogesterone acetate lists thromboembolic disorders as a critical warning, stating "the physician should be alert to the earliest manifestations of thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebrovascular disorders, and retinal thrombosis)" 4. The label explicitly warns that if any thrombotic event occurs or is suspected, "the drug should not be readministered" 4.

Safer Contraceptive Alternatives

This patient should be offered long-acting reversible contraceptives (LARCs) that do not carry the same cardiovascular risks:

• Copper intrauterine device (IUD): Highly effective (<1% failure rate) with no hormonal effects on cardiovascular risk factors 1
• Levonorgestrel IUD: Lower systemic progestin exposure than DMPA, with minimal cardiovascular effects 1
• Progestin-only pills: While the 2007 Diabetes Care guidelines noted increased diabetes risk with progestin-only methods in Latino breastfeeding women 1, this patient is not breastfeeding, and the systemic exposure is lower than DMPA
• Barrier methods with condoms: Provide dual protection against pregnancy and STIs without cardiovascular risk 5, 6

Critical Clinical Pitfall to Avoid

Do not prescribe DMPA based solely on the US Medical Eligibility Criteria Category 3 designation without considering the totality of this patient's risk profile. Category 3 means "theoretical or proven risks usually outweigh the advantages" and requires careful clinical judgment 5. In this case, the combination of uncontrolled hypertension (absolute contraindication per 2025 guidelines 1), age >35 with smoking, and dyslipidemia creates a risk profile where DMPA is clearly contraindicated.

Immediate Management Steps

Before prescribing any contraception, this patient requires:

• Blood pressure control: Achieve BP <140/90 mm Hg before considering any hormonal contraception 1
• Smoking cessation counseling: Essential to reduce cardiovascular risk 1
• Lipid management: Address dyslipidemia through lifestyle modification and potentially statin therapy 1
• Cardiovascular risk stratification: Calculate 10-year ASCVD risk to guide preventive therapy 1

Only after achieving blood pressure control and addressing modifiable risk factors should hormonal contraception be reconsidered, and even then, DMPA should be avoided in favor of methods with lower cardiovascular risk.